Extend your brand profile by curating daily news.

Nutriband Secures USPTO Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

By Advos•
Nutriband received a USPTO Notice of Allowance for brand-name trademarks tied to its abuse-deterrent fentanyl patch, advancing commercialization of a product it projects could reach $80 million to $200 million in peak annual U.S. sales.
Nutriband Secures USPTO Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

Nutriband (NASDAQ: NTRB) announced it received a Notice of Allowance dated Nov. 3, 2026, from the United States Patent and Trademark Office for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The allowance is a procedural milestone in trademark prosecution, and the company said it intends to pursue full trademark registration in the United States and internationally.

The development matters beyond branding. Nutriband is preparing to submit its proposed global brand name to the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities for preapproval review. The company said its naming process emphasizes minimizing potential medication errors associated with similar-looking or similar-sounding drug names, a consideration that carries weight in a category where fentanyl patches are dispensed to patients with serious pain conditions.

The product incorporates Nutriband's proprietary AVERSA technology, designed to deter intentional abuse and misuse of fentanyl patches while reducing accidental exposure risks. According to the company, AVERSA uses aversive agents in transdermal patches to discourage misuse of medications with abuse potential, including opioids and stimulants, and is supported by patents issued in 46 countries. Nutriband estimates potential peak annual U.S. sales of $80 million to $200 million for the product and is pursuing development for international markets.

For readers and investors tracking the opioid-abuse deterrent space, the announcement signals that Nutriband is moving on two fronts at once: securing intellectual property around the commercial identity of its lead asset and laying the regulatory groundwork for a global brand name. Trademark allowance does not itself authorize marketing, and the product remains under development, but the company's stated plan to seek preapproval name review with U.S. and European regulators indicates it is preparing for later-stage filings.

Nutriband describes itself as primarily engaged in developing a portfolio of transdermal pharmaceutical products, with its lead product under development being an abuse-deterrent fentanyl patch incorporating AVERSA. The company maintains a website at www.nutriband.com, and the full press release is available at https://ibn.fm/FN3Or. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB.

The announcement was distributed through BioMedWire, a communications platform focused on biotechnology, biomedical sciences and life sciences that is part of the Dynamic Brand Portfolio at IBN. The platform provides wire solutions through InvestorWire and offers corporate communications solutions to public and private companies. Full terms of use and disclaimers applicable to the content are posted at https://www.BioMedWire.com/Disclaimer.

Advos

Advos

@advos